Cumberland Pharmaceuticals Q2 FY26 net loss widens to USD 4.1 million; revenue falls 56.28% to USD 166,458
CPIX•CPIX•CPIX•CPIX•Total assets were USD 62.88 million at June 30; cash and equivalents were USD 3.86 million.
The company closed a USD 100 million cash sale of its FDA-approved brands to Apotex, and the board declared a USD 1.5-per-share special dividend.
Cumberland Pharmaceuticals posted a GAAP net loss of USD 4.11 million, or USD 0.27 a share, for Q2 2026.
Net loss widened from USD 0.74 million, or USD 0.05 a share, a year earlier.
GAAP net revenues from continuing operations fell 56.28% to USD 166,458.
